Quantity of eligible patients: CDEC discussed the uncertainty in the volume of people with reasonably significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be labeled as possessing mild or average sickness could possibly have a significant https://vong801fhh5.wikiexpression.com/user